1. Home
  2. BNED vs DMAC Comparison

BNED vs DMAC Comparison

Compare BNED & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BNED
  • DMAC
  • Stock Information
  • Founded
  • BNED 1965
  • DMAC 2000
  • Country
  • BNED United States
  • DMAC United States
  • Employees
  • BNED N/A
  • DMAC N/A
  • Industry
  • BNED Other Specialty Stores
  • DMAC Biotechnology: Pharmaceutical Preparations
  • Sector
  • BNED Consumer Discretionary
  • DMAC Health Care
  • Exchange
  • BNED Nasdaq
  • DMAC Nasdaq
  • Market Cap
  • BNED 338.8M
  • DMAC 310.1M
  • IPO Year
  • BNED N/A
  • DMAC N/A
  • Fundamental
  • Price
  • BNED $9.44
  • DMAC $6.68
  • Analyst Decision
  • BNED
  • DMAC Strong Buy
  • Analyst Count
  • BNED 0
  • DMAC 3
  • Target Price
  • BNED N/A
  • DMAC $12.33
  • AVG Volume (30 Days)
  • BNED 261.9K
  • DMAC 285.8K
  • Earning Date
  • BNED 09-12-2025
  • DMAC 11-12-2025
  • Dividend Yield
  • BNED N/A
  • DMAC N/A
  • EPS Growth
  • BNED N/A
  • DMAC N/A
  • EPS
  • BNED N/A
  • DMAC N/A
  • Revenue
  • BNED $1,567,800,000.00
  • DMAC N/A
  • Revenue This Year
  • BNED $2.74
  • DMAC N/A
  • Revenue Next Year
  • BNED N/A
  • DMAC N/A
  • P/E Ratio
  • BNED N/A
  • DMAC N/A
  • Revenue Growth
  • BNED N/A
  • DMAC N/A
  • 52 Week Low
  • BNED $7.90
  • DMAC $3.19
  • 52 Week High
  • BNED $14.41
  • DMAC $7.49
  • Technical
  • Relative Strength Index (RSI)
  • BNED 51.36
  • DMAC 48.53
  • Support Level
  • BNED $9.28
  • DMAC $6.56
  • Resistance Level
  • BNED $9.78
  • DMAC $7.20
  • Average True Range (ATR)
  • BNED 0.33
  • DMAC 0.32
  • MACD
  • BNED -0.04
  • DMAC -0.06
  • Stochastic Oscillator
  • BNED 50.19
  • DMAC 17.65

About BNED Barnes & Noble Education Inc

Barnes & Noble Education Inc is an operator of bookstores in college and university campuses across the United States. The company is also engaged in providing digital education services. It operates in three reportable segments that include Retail offers existing and prospective clients the flexibility of physical, virtual, or custom store solutions, and wholesale is comprised of the wholesale and virtual retail fulfillment, and support operations of the MBS subsidiary, also Corporate Services represent unallocated shared-service costs which include corporate level expenses and other governance functions, including executive functions, such as accounting, legal, treasury, information technology, and human resources. It earns majority of the revenue from Retail segment.

About DMAC DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

Share on Social Networks: